论文部分内容阅读
目的探讨美多芭联合吡贝地尔治疗帕金森病(PD)的临床疗效及安全性。方法选取南充市中心医院2012年6月—2013年12月收治的PD患者47例,随机分为对照组23例和联合组24例。对照组患者给予美多芭治疗,联合组患者在对照组基础上给予吡贝地尔治疗,两组患者均持续治疗48个月。比较两组患者的临床疗效,治疗前、治疗12、24、36、48个月时帕金森氏病综合评分量表(UPDRS)评分及治疗期间药物不良反应发生情况。结果联合组患者临床疗效优于对照组(P<0.05)。治疗前及治疗12个月,两组患者UPDRS评分比较,差异无统计学意义(P>0.05);治疗后24、36、48个月时,联合组患者UPDRS评分低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论美多芭联合吡贝地尔治疗PD的临床疗效确切,可有效降低UPDRS评分,改善患者症状,安全性好。
Objective To investigate the clinical efficacy and safety of metoprolol combined with piribedil in the treatment of Parkinson’s disease (PD). Methods Forty-seven patients with PD who were admitted to Nanchong Central Hospital from June 2012 to December 2013 were randomly divided into control group (23 cases) and combination group (24 cases). Patients in the control group were treated with metoprolol, and patients in the combination group were treated with piribedil on the basis of the control group. Both groups were treated for 48 months. The clinical efficacy of the two groups were compared. The UPDRS score, 12, 24, 36, 48 months before treatment, and the incidence of adverse drug reactions during the treatment were compared. Results The clinical efficacy of the combination group was better than that of the control group (P <0.05). The UPDRS scores of the two groups were not significantly different before treatment and 12 months after treatment (P> 0.05). UPDRS scores in the combined group were lower than those in the control group at 24, 36 and 48 months ). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusions The clinical efficacy of metoprolol combined with piribedil in the treatment of PD is definite, which can effectively reduce the UPDRS score and improve the symptoms and safety of patients.